Within the last two decades, SARS and MERS coronaviruses emerged as global health concerns causing severe acute respiratory syndromes. In December 2019, a novel coronavirus (SARS-CoV-2) was identified in Wuhan, Hubei province in China. The SARS-CoV genome encodes several proteases including papain-like protease 1 (PLP1; PLPro); this key enzyme along with 3CL-protease and PLP2 (PLPro2) drives the early stage of infection by processing a large viral polypeptide into functional enzymes. SARS-CoV PLPro shares 82% in protein sequence identity with PLPro from SARS-CoV-2. Initially, it was reported that SARS PLPro was a deubiquitinase, however subsequent work has shown that PLPro is preferentially a deISGylase. PLPro cleaves ISG15-PLA2 and Ub-PLA2 with high and low efficiency, respectively. The PLPro represents an antiviral drug target for counteracting of SARS-CoV and MERS-CoV infections.
|Molecular Weight||35 kDa|
|Storage||-80°C, avoid freeze/thaw cycles|